Clinical trial · Interventional
Letrozole Dose Increments in PCOS Patients Resistant to Letrozole
Letrozole Dose Increments in PCOS Patients Resistant to Letrozole Ovulation Induction
NCT06403488CI-TRIAL-00076917completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Objectives: To study the effect of Letrozole dose increments on ovulation rate and endometrial thickness as a primary outcomes in patients with polycystic ovary syndrome who previously resistant to letrazole conventional dose, and chemical and clinical pregnancy considered as secondary outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Letrozole 2.5mg | Drug | Letrozole | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- femara 1x3
- description
- Femara 2.5 mg (Novartis pharma ) 3 tablets per day starting from the second day of the menstrual cycle for 5 days
- interventionNames
- Drug: Letrozole 2.5mg
- type
- EXPERIMENTAL
- label
- femara 2x2
- description
- (Femara 2.5 mg (Novartis pharma )2 tablets twice daily for 5 days starting from the second day of the cycle
- interventionNames
- Drug: Letrozole 2.5mg
Primary outcomes (2)
- measure
- ovulation rate
- timeFrame
- 1 month
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * normal semen analysis of their male partner * Diagnosis of PCOS based on a modified form of the Rotterdam criteria Exclusion Criteria: * Any contraindications for pregnancy * patients received other medications for ovulation induction such as metformin or clomiphene citrate and gonadotropins concomitantly * hyperprolactinemia * abnormal thyroid functions * multiple uterine fibroids
References
Publications (0)
Data not yet available
No reference posted for this study.